Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

Inclusion Criteria: * Willing \& able to provide \& understand written informed consent * Healthy male or non-pregnant, non-lactating female at least 18 years of age and older * Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or that is predominantly interdigital but may extend to other areas * Tinea pedis provisionally confirmed at baseline by positive potassium hydroxide (KOH)wet mount preparation showing segmented fungal hyphae * Has sum of the clinical signs and symptoms scores of the target lesion of at least 4, including a minimum score of 2 for erythema \& a minimum score of 2 for scaling or pruritus * Currently in general good health with no clinically significant disease * Willing and able to understand and comply with study requirements * Women of childbearing potential must have a negative urine pregnancy test and be willing to use an acceptable form of birth control during study Exclusion Criteria: * Females who are pregnant, breastfeeding, planning a pregnancy, or do not agree to use an acceptable form of birth control during the study * Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface * Presence of any other infection of the foot or other disease that might confound treatment evaluation * History of dermatophyte infections unresponsive to antifungal drugs * Known hypersensitivity to Butenafine Hydrochloride or any component of the study medications * Use of antipruritics, topical systemic corticosteroid, antibiotic or antifungal therapy, oral terbinafine or itraconazole, or immunosuppressive medication or radiation therapy more recently than indicated washout period * Current oral, vaginal, or mucocutaneous candidiasis * Current bacterial skin infection, secondary cellulitis, lymphangitis, or pyoderma * Presence of current conditions that require systemic antimicrobial or antifungal therapy * Uncontrolled diabetes mellitus, peripheral vascular disease, chronic venous stasis, or other significant condition * Current severe onychomycosis * Any clinically significant condition or situation, other than condition being studied, that would interfere with the study evaluations or participation * Use of any investigational drugs or device within 30 days of signing Informed Consent Form (ICF) * Current participation in any other clinical study * Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would compromise compliance * Previous participation in this study * Subjects with past history of tinea pedis with lack of response to antifungal therapy * Subjects who in Investigator's opinion would be non-compliant * Employees or direct relatives of an employee of the study center or Investigator